{"id":"avacincaptad","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Conjunctival hemorrhage","drugRate":"17%","severity":"common","organSystem":""},{"effect":"Blurred vision","drugRate":"14%","severity":"common","organSystem":""},{"effect":"Increased IOP","drugRate":"13%","severity":"common","organSystem":""},{"effect":"Choroidal neovascularization","drugRate":"12%","severity":"common","organSystem":""},{"effect":"Punctate keratitis","drugRate":"10%","severity":"common","organSystem":""},{"effect":"Eye pain","drugRate":"7%","severity":"common","organSystem":""},{"effect":"Retinal hemorrhage","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Vitreous floaters","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Ocular hypertension","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Blepharitis","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Corneal abrasion","drugRate":"2%","severity":"common","organSystem":""}],"contraindications":["Ocular or periocular infection","Uveitis"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Endophthalmitis","drugRate":"1%","severity":"serious"},{"effect":"Retinal detachment","drugRate":"1%","severity":"serious"},{"effect":"Vitreous hemorrhage","drugRate":"1%","severity":"serious"},{"effect":"Vitritis","drugRate":"1%","severity":"serious"},{"effect":"Optic ischemic neuropathy","drugRate":"1%","severity":"serious"},{"effect":"Photopsia","drugRate":"1%","severity":"serious"},{"effect":"Vitreal cells","drugRate":"1%","severity":"serious"}]},"trials":[],"_chembl":null,"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":{"setId":"1642fe6a-dc26-4d20-ae6e-654af744e3bd","title":"IZERVAY (AVACINCAPTAD PEGOL) INJECTION [ASTELLAS PHARMA US, INC.]"},"ecosystem":[],"mechanism":{"target":"Complement C5"},"_scrapedAt":"2026-03-28T02:30:08.227Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Geographic atrophy secondary to age-related macular degeneration","diseaseId":"geographic-atrophy-secondary-to-age-related-macular-degeneration","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05536297","phase":"PHASE3","title":"Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2022-09-26","conditions":"Geographic Atrophy, Age-Related Macular Degeneration","enrollment":278},{"nctId":"NCT03364153","phase":"PHASE2","title":"Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-01-12","conditions":"Stargardt's Macular Dystrophy","enrollment":121},{"nctId":"NCT06961370","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-07-16","conditions":"Geographic Atrophy, Age-related Macular Degeneration","enrollment":132},{"nctId":"NCT06779773","phase":"","title":"A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-01-22","conditions":"Geographic Atrophy, Macular Degeneration","enrollment":1000},{"nctId":"NCT06970665","phase":"PHASE4","title":"A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration","status":"RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2025-07-08","conditions":"Geographic Atrophy, Age-Related Macular Degeneration","enrollment":20},{"nctId":"NCT06659445","phase":"PHASE2","title":"Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD","status":"RECRUITING","sponsor":"ONL Therapeutics","startDate":"2025-10-28","conditions":"Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)","enrollment":324},{"nctId":"NCT05839041","phase":"PHASE2","title":"A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aviceda Therapeutics, Inc.","startDate":"2023-05-02","conditions":"Geographic Atrophy of the Macula, Macular Degeneration","enrollment":300},{"nctId":"NCT04435366","phase":"PHASE3","title":"A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)","status":"COMPLETED","sponsor":"IVERIC bio, Inc.","startDate":"2020-06-22","conditions":"Geographic Atrophy, Macular Degeneration","enrollment":448},{"nctId":"NCT03362190","phase":"PHASE2","title":"ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)","status":"COMPLETED","sponsor":"Ophthotech Corporation","startDate":"2017-10-11","conditions":"Neovascular Age-related Macular Degeneration","enrollment":64},{"nctId":"NCT02686658","phase":"PHASE2, PHASE3","title":"Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"IVERIC bio, Inc.","startDate":"2015-12-15","conditions":"Geographic Atrophy, Dry Age-Related Macular Degeneration","enrollment":286},{"nctId":"NCT02397954","phase":"PHASE2","title":"A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)","status":"COMPLETED","sponsor":"Ophthotech Corporation","startDate":"2015-03-12","conditions":"Idiopathic Polypoidal Choroidal Vasculopathy","enrollment":4},{"nctId":"NCT05571267","phase":"PHASE2","title":"Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD","status":"TERMINATED","sponsor":"IVERIC bio, Inc.","startDate":"2016-10-20","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":1},{"nctId":"NCT00709527","phase":"PHASE1","title":"ARC1905 (Anti-C5 Aptamer) Given With Lucentis 0.5 mg In People With Neovascular Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Ophthotech Corporation","startDate":"2008-10-16","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":60},{"nctId":"NCT00950638","phase":"PHASE1","title":"A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Ophthotech Corporation","startDate":"2009-07-16","conditions":"Dry Age-Related Macular Degeneration","enrollment":47},{"nctId":"NCT03374670","phase":"PHASE2","title":"ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)","status":"WITHDRAWN","sponsor":"Ophthotech Corporation","startDate":"2018-11","conditions":"Idiopathic Polypoidal Choroidal Vasculopathy","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":69,"therapeuticAreas":["Ophthalmology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Avacincaptad","genericName":"Avacincaptad","companyName":"Aviceda Therapeutics, Inc.","companyId":"aviceda-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}